Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) traded up 3.6% on Wednesday . The company traded as high as $41.90 and last traded at $41.50, with a volume of 235,556 shares trading hands. The stock had previously closed at $40.06.

A number of research firms have commented on AGIO. Credit Suisse Group AG reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Sunday, March 27th. Canaccord Genuity upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from $50.00 to $90.00 in a research note on Monday, June 13th. Janney Montgomery Scott reiterated a “neutral” rating and issued a $47.00 target price (down from $52.00) on shares of Agios Pharmaceuticals in a research note on Monday, June 13th. SunTrust Banks Inc. upped their target price on Agios Pharmaceuticals from $57.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, May 18th. Finally, Cowen and Company reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, May 24th. Six analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $69.67.

The stock’s 50-day moving average is $48.11 and its 200 day moving average is $45.79. The stock’s market cap is $1.61 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.18. The firm had revenue of $31.30 million for the quarter, compared to analyst estimates of $20.94 million. The business’s revenue was down 8.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.13) EPS. On average, equities analysts predict that Agios Pharmaceuticals Inc. will post ($3.46) earnings per share for the current year.

In other news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, April 26th. The shares were sold at an average price of $53.44, for a total transaction of $133,813.76. Following the transaction, the director now owns 128,429 shares in the company, valued at $6,863,245.76. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Scott Biller sold 27,500 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total transaction of $1,787,500.00. Following the transaction, the insider now owns 81,376 shares in the company, valued at approximately $5,289,440. The disclosure for this sale can be found here.

Other institutional investors have recently made changes to their positions in the company. BB Biotech AG boosted its position in shares of Agios Pharmaceuticals by 2.4% in the fourth quarter. BB Biotech AG now owns 2,159,921 shares of the biopharmaceutical company’s stock worth $140,222,000 after buying an additional 50,000 shares in the last quarter. Columbia Wanger Asset Management LLC boosted its position in shares of Agios Pharmaceuticals by 11.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 436,994 shares of the biopharmaceutical company’s stock worth $28,370,000 after buying an additional 44,861 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Agios Pharmaceuticals by 170.6% in the fourth quarter. Jennison Associates LLC now owns 430,085 shares of the biopharmaceutical company’s stock worth $27,921,000 after buying an additional 271,142 shares in the last quarter. GAM Holding AG boosted its position in shares of Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock worth $2,967,000 after buying an additional 31,000 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Agios Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 31,258 shares of the biopharmaceutical company’s stock worth $2,029,000 after buying an additional 1,740 shares in the last quarter.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.